Delivery Order SPE2DB25D3008-SPE2DB25FRDDG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $16,244.96. This is a firm fixed-price delivery order with an ultimate completion date of October 15, 2025, and represents a non-competitive set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 100 mg tablets in 7-count packaging, with a contract ceiling value of $24,367.44 and completion date of October 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with the federal government. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibrance 75 mg tablets in a quantity of seven units, with a ceiling value of $32,495.84. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for ultimate completion on October 8, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ibrance 100 mg capsules (21-count packages) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which is expected to be completed by June 24, 2025, carries no set-aside designation and represents a competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets in quantities of seven units. This firm fixed price delivery order, valued at $32,489.92, represents a competitive award with no set-aside designation and is scheduled for completion by September 24, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units, with a contract ceiling value of $8,123.96. This competitively awarded, firm fixed-price delivery order is set to be completed by September 24, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-count), valued at $8,122.48 under a firm fixed price contract. This non-set-aside delivery order is scheduled for completion by September 3, 2025, with performance of work occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRDDGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was competitively awarded with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, supporting the federal government's pharmaceutical supply chain for military and defense healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally, enabling the company to supply a broad range of medications, vaccines, medical devices, and healthcare commodities to support military healthcare programs. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in fulfilling defense medical procurement requirements across multiple therapeutic domains, with this specific order for Ibrance supporting oncology treatment needs within the Defense Health Agency and related military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/3/25 |